Cargando…
Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity
BACKGROUND: This work aimed to synthesize a cathepsin B (CTSB)-cleavable tumor-targeting prodrug peptide doxorubicin (PDOX) and study the in vivo efficacy and toxicities on an animal model of gastric peritoneal carcinomatosis (PC). METHODS: PDOX was synthesized using doxorubicin (DOX) attaching to a...
Autores principales: | Tang, Li, Duan, Rui, Zhong, Yan-jun, Firestone, Raymond A, Hong, Ya-ping, Li, Ji-guo, Xin, Yan-chao, Wu, Han-lin, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984748/ https://www.ncbi.nlm.nih.gov/pubmed/24588871 http://dx.doi.org/10.1186/1476-4598-13-44 |
Ejemplares similares
-
Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study
por: Wang, Qun, et al.
Publicado: (2013) -
Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer
por: Zhang, Jue, et al.
Publicado: (2017) -
Establishment and identification of a rabbit model of peritoneal carcinomatosis from gastric cancer
por: Mei, Lie-Jun, et al.
Publicado: (2010) -
Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
por: Simón-Gracia, Lorena, et al.
Publicado: (2018) -
Hyaluronan-binding peptide for targeting peritoneal carcinomatosis
por: Ikemoto, Hideki, et al.
Publicado: (2017)